These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38733643)

  • 1. HTA criteria adopted in different models of public healthcare systems for orphan drugs: A scoping review.
    Felippini A; Biglia LV; Lima TM; Aguiar PM
    Health Policy; 2024 Jun; 144():105080. PubMed ID: 38733643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
    Zelei T; Molnár MJ; Szegedi M; Kaló Z
    Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methods and criteria for the assessment of orphan drugs: a scoping review.
    Mohammadshahi M; Olyaeemanesh A; Ehsani-Chimeh E; Mobinizadeh M; Fakoorfard Z; Akbari Sari A; Aghighi M
    Int J Technol Assess Health Care; 2022 Jun; 38(1):e59. PubMed ID: 35730573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European Countries.
    Nicod E; Berg Brigham K; Durand-Zaleski I; Kanavos P
    Value Health; 2017; 20(7):919-926. PubMed ID: 28712621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
    Hughes-Wilson W; Palma A; Schuurman A; Simoens S
    Orphanet J Rare Dis; 2012 Sep; 7():74. PubMed ID: 23013790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe.
    Kawalec P; Sagan A; Pilc A
    Orphanet J Rare Dis; 2016 Sep; 11(1):122. PubMed ID: 27600717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HTA decision-making for drugs for rare diseases: comparison of processes across countries.
    Stafinski T; Glennie J; Young A; Menon D
    Orphanet J Rare Dis; 2022 Jul; 17(1):258. PubMed ID: 35804398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Market access for medicines treating rare diseases: Association between specialised processes for orphan medicines and funding recommendations.
    Fontrier AM
    Soc Sci Med; 2022 Aug; 306():115119. PubMed ID: 35700552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of orphan drugs prices in France: a regression analysis.
    Korchagina D; Millier A; Vataire AL; Aballea S; Falissard B; Toumi M
    Orphanet J Rare Dis; 2017 Apr; 12(1):75. PubMed ID: 28427466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review.
    Lasalvia P; Prieto-Pinto L; Moreno M; Castrillón J; Romano G; Garzón-Orjuela N; Rosselli D
    Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):409-420. PubMed ID: 31210065
    [No Abstract]   [Full Text] [Related]  

  • 12. Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category?
    Adkins EM; Nicholson L; Floyd D; Ratcliffe M; Chevrou-Severac H
    Clinicoecon Outcomes Res; 2017; 9():327-342. PubMed ID: 28652787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The implementation of health technology assessment principles in public decisions concerning orphan drugs.
    Brenna E; Polistena B; Spandonaro F
    Eur J Clin Pharmacol; 2020 Jun; 76(6):755-764. PubMed ID: 32219539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel approach to decision making for orphan drugs.
    Decker B; Mlcoch T; Pustovalova A; Dolezal T
    Int J Technol Assess Health Care; 2023 Feb; 39(1):e10. PubMed ID: 36748356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reimbursement of Drugs for Rare Diseases through the Public Healthcare System in Canada: Where Are We Now?
    Menon D; Clark D; Stafinski T
    Healthc Policy; 2015 Aug; 11(1):15-32. PubMed ID: 26571466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.
    Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B
    Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
    Nicod E
    Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Development of the Romanian Scorecard HTA System.
    Radu CP; Chiriac ND; Pravat AM
    Value Health Reg Issues; 2016 Sep; 10():41-47. PubMed ID: 27881276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical assessment of belgian reimbursement dossiers of orphan drugs.
    Denis A; Mergaert L; Fostier C; Cleemput I; Hulstaert F; Simoens S
    Pharmacoeconomics; 2011 Oct; 29(10):883-93. PubMed ID: 21905759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review.
    Grand TS; Ren S; Hall J; Åström DO; Regnier S; Thokala P
    Pharmacoeconomics; 2024 Jun; 42(6):619-631. PubMed ID: 38616217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.